News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
FDA to Take Action Against Mass-Marketing of Illegal Copycat Drugs: Report
2
TrumpRx Is Live and Complicated
3
Novo Nordisk Launches First Super Bowl Commercial for Wegovy Pill
4
Eli Lilly Enters $8.5 Billion Strategic Collaboration with Innovent Biologics and Acquires Orna Therapeutics
5